Europe
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
The positive results are spurring the companies to begin seeking approval for the checkpoint inhibitor.
The company’s vaccine controversy could cause legal and image problems for years to come.
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.
The success has prompted Roche to exercise its option to license the product, called IONIS-HTT(Rx), at a cost of $45 million.
According to the DoD statement, the contract is for one year with five options to extend the contract for an additional year.
As Sanofi grapples with the fallout from its Dengue vaccine, the termination of its late-stage C. diff vaccine and falling short of its third quarter expectations, company investors are getting antsy for some good news.
The deal is expected to close in the first quarter of 2018.
Medtronic confirmed that it bought Crospon but declined to disclose the value of the deal.
PRESS RELEASES